Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD40L TIL and Nivolumab in Advanced NSCLC
NCT05681780Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2023
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD40 ligand-augmented tumor-infiltrating lymphocytes in non-small cell lung cancer (NSCLC), sponsored by Moffitt Cancer Center. Primary endpoint: Adverse Events up to 18 Months. Started Mar 2023; status: recruiting.
02
Drugs
CD40 ligand-augmented tumor-infiltrating lymphocytes
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05681780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05681780.